Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 38 |
| Active Pipeline (Recruiting Now) | 23 (12) |
| Completed vs Stopped Early | 7 / 7 (18.4%) |
| Median Closed Actual Enrollment | 49 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Oklahoma Health Sciences Center | Oklahoma City, OK | 6 |
| University of Virginia Cancer Center | Charlottesville, VA | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the University of Oklahoma Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.